219 related articles for article (PubMed ID: 32025027)
1. Ibrutinib treatment inhibits breast cancer progression and metastasis by inducing conversion of myeloid-derived suppressor cells to dendritic cells.
Varikuti S; Singh B; Volpedo G; Ahirwar DK; Jha BK; Saljoughian N; Viana AG; Verma C; Hamza O; Halsey G; Holcomb EA; Maryala RJ; Oghumu S; Ganju RK; Satoskar AR
Br J Cancer; 2020 Mar; 122(7):1005-1013. PubMed ID: 32025027
[TBL] [Abstract][Full Text] [Related]
2. Myeloid-Derived Suppressor Cells Express Bruton's Tyrosine Kinase and Can Be Depleted in Tumor-Bearing Hosts by Ibrutinib Treatment.
Stiff A; Trikha P; Wesolowski R; Kendra K; Hsu V; Uppati S; McMichael E; Duggan M; Campbell A; Keller K; Landi I; Zhong Y; Dubovsky J; Howard JH; Yu L; Harrington B; Old M; Reiff S; Mace T; Tridandapani S; Muthusamy N; Caligiuri MA; Byrd JC; Carson WE
Cancer Res; 2016 Apr; 76(8):2125-36. PubMed ID: 26880800
[TBL] [Abstract][Full Text] [Related]
3. Ibrutinib in Gynecological Malignancies and Breast Cancer: A Systematic Review.
Metzler JM; Burla L; Fink D; Imesch P
Int J Mol Sci; 2020 Jun; 21(11):. PubMed ID: 32532074
[TBL] [Abstract][Full Text] [Related]
4. Therapeutic treatment with Ibrutinib attenuates imiquimod-induced psoriasis-like inflammation in mice through downregulation of oxidative and inflammatory mediators in neutrophils and dendritic cells.
Al-Harbi NO; Nadeem A; Ahmad SF; Bakheet SA; El-Sherbeeny AM; Ibrahim KE; Alzahrani KS; Al-Harbi MM; Mahmood HM; Alqahtani F; Attia SM; Alotaibi MR
Eur J Pharmacol; 2020 Jun; 877():173088. PubMed ID: 32234429
[TBL] [Abstract][Full Text] [Related]
5. Destabilization of ROR1 enhances activity of Ibrutinib against chronic lymphocytic leukemia in vivo.
Liu Z; Liu J; Zhang T; Shi M; Chen X; Chen Y; Yu J
Pharmacol Res; 2020 Jan; 151():104512. PubMed ID: 31726100
[TBL] [Abstract][Full Text] [Related]
6. Ibrutinib in the Treatment of Solid Tumors: Current State of Knowledge and Future Directions.
Szklener K; Michalski A; Żak K; Piwoński M; Mańdziuk S
Cells; 2022 Apr; 11(8):. PubMed ID: 35456016
[TBL] [Abstract][Full Text] [Related]
7. Bruton's Tyrosine Kinase Inhibitors Prevent Therapeutic Escape in Breast Cancer Cells.
Wang X; Wong J; Sevinsky CJ; Kokabee L; Khan F; Sun Y; Conklin DS
Mol Cancer Ther; 2016 Sep; 15(9):2198-208. PubMed ID: 27256378
[TBL] [Abstract][Full Text] [Related]
8. Ibrutinib treatment improves T cell number and function in CLL patients.
Long M; Beckwith K; Do P; Mundy BL; Gordon A; Lehman AM; Maddocks KJ; Cheney C; Jones JA; Flynn JM; Andritsos LA; Awan F; Fraietta JA; June CH; Maus MV; Woyach JA; Caligiuri MA; Johnson AJ; Muthusamy N; Byrd JC
J Clin Invest; 2017 Aug; 127(8):3052-3064. PubMed ID: 28714866
[TBL] [Abstract][Full Text] [Related]
9. Activity of Bruton's tyrosine-kinase inhibitor ibrutinib in patients with CD117-positive acute myeloid leukaemia: a mechanistic study using patient-derived blast cells.
Rushworth SA; Pillinger G; Abdul-Aziz A; Piddock R; Shafat MS; Murray MY; Zaitseva L; Lawes MJ; MacEwan DJ; Bowles KM
Lancet Haematol; 2015 May; 2(5):e204-11. PubMed ID: 26688095
[TBL] [Abstract][Full Text] [Related]
10. Emerging bruton tyrosine kinase inhibitors for chronic lymphocytic leukaemia: one step ahead ibrutinib.
Molica S; Gianfelici V; Levato L
Expert Opin Emerg Drugs; 2020 Mar; 25(1):25-35. PubMed ID: 31996046
[No Abstract] [Full Text] [Related]
11. Impact of long-term ibrutinib treatment on circulating immune cells in previously untreated chronic lymphocytic leukemia.
Solman IG; Blum LK; Burger JA; Kipps TJ; Dean JP; James DF; Mongan A
Leuk Res; 2021 Mar; 102():106520. PubMed ID: 33611131
[TBL] [Abstract][Full Text] [Related]
12. Targeting the IL-2 inducible kinase in melanoma; a phase 2 study of ibrutinib in systemic treatment-refractory distant metastatic cutaneous melanoma: preclinical rationale, biology, and clinical activity (NCI9922).
Moschos SJ; Eroglu Z; Khushalani NI; Kendra KL; Ansstas G; In GK; Wang P; Liu G; Collichio FA; Googe PB; Carson CC; McKinnon K; Wang HH; Nikolaishvilli-Feinberg N; Ivanova A; Arrowood CC; Garrett-Mead N; Conway KC; Edmiston SN; Ollila DW; Serody JS; Thomas NE; Ivy SP; Agrawal L; Dees EC; Abbruzzese JL
Melanoma Res; 2021 Apr; 31(2):162-172. PubMed ID: 33661190
[TBL] [Abstract][Full Text] [Related]
13. Inhibition of effector B cells by ibrutinib in systemic sclerosis.
Einhaus J; Pecher AC; Asteriti E; Schmid H; Secker KA; Duerr-Stoerzer S; Keppeler H; Klein R; Schneidawind C; Henes J; Schneidawind D
Arthritis Res Ther; 2020 Mar; 22(1):66. PubMed ID: 32228672
[TBL] [Abstract][Full Text] [Related]
14. Visualization and quantification of
Hoffmann SHL; Reck DI; Maurer A; Fehrenbacher B; Sceneay JE; Poxleitner M; Öz HH; Ehrlichmann W; Reischl G; Fuchs K; Schaller M; Hartl D; Kneilling M; Möller A; Pichler BJ; Griessinger CM
Theranostics; 2019; 9(20):5869-5885. PubMed ID: 31534525
[TBL] [Abstract][Full Text] [Related]
15. Inhibition of Bruton's tyrosine kinase and IL-2 inducible T-cell kinase suppresses both neutrophilic and eosinophilic airway inflammation in a cockroach allergen extract-induced mixed granulocytic mouse model of asthma using preventative and therapeutic strategy.
Nadeem A; Ahmad SF; Al-Harbi NO; Ibrahim KE; Siddiqui N; Al-Harbi MM; Attia SM; Bakheet SA
Pharmacol Res; 2019 Oct; 148():104441. PubMed ID: 31505252
[TBL] [Abstract][Full Text] [Related]
16. CXCL17-derived CD11b
Hsu YL; Yen MC; Chang WA; Tsai PH; Pan YC; Liao SH; Kuo PL
Breast Cancer Res; 2019 Feb; 21(1):23. PubMed ID: 30755260
[TBL] [Abstract][Full Text] [Related]
17. Ibrutinib enhances IL-17 response by modulating the function of bone marrow derived dendritic cells.
Natarajan G; Terrazas C; Oghumu S; Varikuti S; Dubovsky JA; Byrd JC; Satoskar AR
Oncoimmunology; 2016; 5(1):e1057385. PubMed ID: 26942065
[TBL] [Abstract][Full Text] [Related]
18. Periostin promotes immunosuppressive premetastatic niche formation to facilitate breast tumour metastasis.
Wang Z; Xiong S; Mao Y; Chen M; Ma X; Zhou X; Ma Z; Liu F; Huang Z; Luo Q; Ouyang G
J Pathol; 2016 Aug; 239(4):484-95. PubMed ID: 27193093
[TBL] [Abstract][Full Text] [Related]
19. Ibrutinib Inhibits ERBB Receptor Tyrosine Kinases and HER2-Amplified Breast Cancer Cell Growth.
Chen J; Kinoshita T; Sukbuntherng J; Chang BY; Elias L
Mol Cancer Ther; 2016 Dec; 15(12):2835-2844. PubMed ID: 27678331
[TBL] [Abstract][Full Text] [Related]
20. Suppressive role of myeloid-derived suppressor cells (MDSCs) in the microenvironment of breast cancer and targeted immunotherapies.
Shou D; Wen L; Song Z; Yin J; Sun Q; Gong W
Oncotarget; 2016 Sep; 7(39):64505-64511. PubMed ID: 27542274
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]